When evaluating the effects of probenecid the nurse should monitor which laboratory result

1. Dalbeth N., Merriman T.R., Stamp L.K. Gout Lancet. 2016;388(10055):2039–2052. [PubMed] [Google Scholar]

2. Emmerson B.T. The management of gout. New Engl J Med. 1996;334(7):445–451. [PubMed] [Google Scholar]

3. Pascual E., Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis. 2007;66(8):1056–1058. [PMC free article] [PubMed] [Google Scholar]

4. Singh J.A. Challenges faced by patients in gout treatment: a qualitative study. J Clin Rheumatol: Practical Rep Rheum Musculoskelet Dis. 2014;20(3):172–174. [PMC free article] [PubMed] [Google Scholar]

5. Kuo C.F., Grainge M.J., Zhang W., Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–662. [PubMed] [Google Scholar]

6. McCarty D.J., Hollander J.L. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452–460. [PubMed] [Google Scholar]

7. Mandal A.K., Mount D.B. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323–345. [PubMed] [Google Scholar]

8. Kamei K., Konta T., Hirayama A., Suzuki K., Ichikawa K., Fujimoto S. A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol, Dialysis, Transplant: official publication of the European Dialysis and Transplant Association – European Renal Association. 2014;29(12):2286–2292. [PubMed] [Google Scholar]

9. Torres R.J., Puig J.G. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis. 2007;2:48. [PMC free article] [PubMed] [Google Scholar]

10. Reginato A.M., Olsen B.R. Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear? Curr Opin Rheumatol. 2007;19(2):134–145. [PubMed] [Google Scholar]

11. Kanbara A., Seyama I. Effect of urine pH on uric acid excretion by manipulating food materials. Nucleosides, Nucleotides Nucleic Acids. 2011;30(12):1066–1071. [PubMed] [Google Scholar]

12. Towiwat P., Li Z.G. The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout. Int J Rheum Dis. 2015;18(5):495–501. [PubMed] [Google Scholar]

13. Mahmoud H.H., Leverger G., Patte C., Harvey E., Lascombes F. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer. 1998;77(Suppl 4):18–20. [PMC free article] [PubMed] [Google Scholar]

14. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998;57(9):509–510. [PMC free article] [PubMed] [Google Scholar]

15. Bedir A., Topbas M., Tanyeri F., Alvur M., Arik N. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J. 2003;44(4):527–536. [PubMed] [Google Scholar]

16. Dessein P.H., Shipton E.A., Stanwix A.E., Joffe B.I., Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59(7):539–543. [PMC free article] [PubMed] [Google Scholar]

17. Ichida K., Matsuo H., Takada T., Nakayama A., Murakami K., Shimizu T. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nature Commun. 2012;3:764. [PMC free article] [PubMed] [Google Scholar]

18. Enomoto A., Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol. 2005;9(3):195–205. [PubMed] [Google Scholar]

19. Bobulescu I.A., Moe O.W. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19(6):358–371. [PMC free article] [PubMed] [Google Scholar]

20. Han J., Liu Y., Rao F., Nievergelt C.M., O'Connor D.T., Wang X. Common genetic variants of the human uromodulin gene regulate transcription and predict plasma uric acid levels. Kidney Int. 2013;83(4):733–740. [PMC free article] [PubMed] [Google Scholar]

21. Cho S.K., Kim S., Chung J.Y., Jee S.H. Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1. BMJ Open. 2015;5(11):e009360. [PMC free article] [PubMed] [Google Scholar]

22. Tan P.K., Ostertag T.M., Miner J.N. Mechanism of high affinity inhibition of the human urate transporter URAT1. Sci Rep. 2016;6:34995. [PMC free article] [PubMed] [Google Scholar]

23. Phipps-Green A.J., Merriman M.E., Topless R., Altaf S., Montgomery G.W., Franklin C. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann Rheum Dis. 2016;75(1):124–130. [PubMed] [Google Scholar]

24. Kolz M., Johnson T., Sanna S., Teumer A., Vitart V., Perola M. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5(6):e1000504. [PMC free article] [PubMed] [Google Scholar]

25. Liu R., O'Connell M., Johnson K., Pritzker K., Mackman N., Terkeltaub R. Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum. 2000;43(5):1145–1155. [PubMed] [Google Scholar]

26. Cronstein B.N., Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol: Practical Rep Rheumat Musculoskelet Dis. 2013;19(1):19–29. [PMC free article] [PubMed] [Google Scholar]

27. Busso N., Ea H.K. The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis) Reumatismo. 2012;63(4):230–237. [PubMed] [Google Scholar]

28. Ea H.K. Mechanisms of gout inflammation. Presse Med. 2011;40(9 Pt 1):836–843. [PubMed] [Google Scholar]

29. Dalbeth N., Lauterio T.J., Wolfe H.R. Mechanism of action of colchicine in the treatment of gout. Clin Ther. 2014;36(10):1465–1479. [PubMed] [Google Scholar]

30. Steiger S., Harper J.L. Mechanisms of spontaneous resolution of acute gouty inflammation. Curr Rheumatol Rep. 2014;16(1):392. [PubMed] [Google Scholar]

31. Grassi W., De Angelis R. Clinical features of gout. Reumatismo. 2012;63(4):238–245. [PubMed] [Google Scholar]

32. Gonzalez E.B. An update on the pathology and clinical management of gouty arthritis. Clin Rheumatol. 2012;31(1):13–21. [PMC free article] [PubMed] [Google Scholar]

33. Schlesinger N., Thiele R.G. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010;69(11):1907–1912. [PubMed] [Google Scholar]

34. Kosmadakis G., Viskaduraki M., Michail S. The validity of fractional excretion of uric acid in the diagnosis of acute kidney injury due to decreased kidney perfusion. Am J Kidney Dis. 2009;54(6):1186–1187. [PubMed] [Google Scholar]

35. Burns C.M., Wortmann R.L. Latest evidence on gout management: what the clinician needs to know. Therap Adv Chronic Dis. 2012;3(6):271–286. [PMC free article] [PubMed] [Google Scholar]

36. Kanbay M., Huddam B., Azak A., Solak Y., Kadioglu G.K., Kirbas I. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol: CJASN. 2011;6(8):1887–1894. [PMC free article] [PubMed] [Google Scholar]

37. Luk A.J., Levin G.P., Moore E.E., Zhou X.H., Kestenbaum B.R., Choi H.K. Allopurinol and mortality in hyperuricaemic patients. Rheumatol (Oxford, England) 2009;48(7):804–806. [PMC free article] [PubMed] [Google Scholar]

38. Yokose C., Chen M., Berhanu A., Pillinger M.H., Krasnokutsky S. Gout and osteoarthritis: associations, pathophysiology, and therapeutic implications. Curr Rheumatol Rep. 2016;18(10):65. [PubMed] [Google Scholar]

39. Mazzali M., Kanbay M., Segal M.S., Shafiu M., Jalal D., Feig D.I. Uric acid and hypertension: cause or effect? Curr Rheumatol Rep. 2010;12(2):108–117. [PubMed] [Google Scholar]

40. Katsiki N., Papanas N., Fonseca V.A., Maltezos E., Mikhailidis D.P. Uric acid and diabetes: Is there a link? Curr Pharm Des. 2013;19(27):4930–4937. [PubMed] [Google Scholar]

41. Roddy E. Revisiting the pathogenesis of podagra: why does gout target the foot? J Foot Ankle Res. 2011;4(1):13. [PMC free article] [PubMed] [Google Scholar]

42. Canoso J.J., Yood R.A. Acute gouty bursitis: report of 15 cases. Ann Rheum Dis. 1979;38(4):326–328. [PMC free article] [PubMed] [Google Scholar]

43. Perez-Ruiz F., Castillo E., Chinchilla S.P., Herrero-Beites A.M. Clinical manifestations and diagnosis of gout. Rheum Dis Clin North Am. 2014;40(2):193–206. [PubMed] [Google Scholar]

44. Pascual E., Batlle-Gualda E., Martinez A., Rosas J., Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med. 1999;131(10):756–759. [PubMed] [Google Scholar]

45. Chhana A., Dalbeth N. The gouty tophus: a review. Curr Rheumatol Rep. 2015;17(3):19. [PubMed] [Google Scholar]

46. Malik A., Schumacher H.R., Dinnella J.E., Clayburne G.M. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol: Practical Rep Rheum Musculoskelet Dis. 2009;15(1):22–24. [PubMed] [Google Scholar]

47. Zhang W., Doherty M., Pascual E., Bardin T., Barskova V., Conaghan P. EULAR evidence based recommendations for gout. Part I: diagnosis. report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT) Ann Rheum Dis. 2006;65(10):1301–1311. [PMC free article] [PubMed] [Google Scholar]

48. Atdjian M., Fernandez-Madrid F. Coexistence of chronic tophaceous gout and rheumatoid arthritis. J Rheumatol. 1981;8(6):989–992. [PubMed] [Google Scholar]

49. Dincer H.E., Dincer A.P., Levinson D.J. Asymptomatic hyperuricemia: to treat or not to treat. Clevel Clin J Med. 2002;69(8):594. 7, 600-2 passim. [PubMed] [Google Scholar]

50. Badulescu M., Macovei L., Rezus E. Acute gout attack with normal serum uric acid levels. Rev Med Chir Soc Med Nat Iasi. 2014;118(4):942–945. [PubMed] [Google Scholar]

51. Underwood M. Diagnosis and management of gout. BMJ (Clin Res Ed) 2006;332(7553):1315–1319. [PMC free article] [PubMed] [Google Scholar]

52. Pascual E., Tovar J., Ruiz M.T. The ordinary light microscope: an appropriate tool for provisional detection and identification of crystals in synovial fluid. Ann Rheum Dis. 1989;48(12):983–985. [PMC free article] [PubMed] [Google Scholar]

53. Phelps P., Steele A.D., McCarty D.J., Jr. Compensated polarized light microscopy. Identification of crystals in synovial fluids from gout and pseudogout. JAMA. 1968;203(7):508–512. [PubMed] [Google Scholar]

54. Strasinger S.K., Di Lorenzo M.S. F. A. Davis Company; 2008. Urinalysis & body fluids. [Google Scholar]

55. Kramer H.M., Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis. 2002;40(1):37–42. [PubMed] [Google Scholar]

56. Fernandes EA, Bergamaschi SB, Rodrigues TC, Dias GC, Malmann R, Ramos GM, et al. Relevant aspects of imaging in the diagnosis and management of gout. Revista brasileira de reumatologia. 2016. [PubMed]

57. Rettenbacher T., Ennemoser S., Weirich H., Ulmer H., Hartig F., Klotz W. Diagnostic imaging of gout: comparison of high-resolution US versus conventional X-ray. Eur Radiol. 2008;18(3):621–630. [PubMed] [Google Scholar]

58. Namas R., Meysami A., Siegal D., Rubin B. Gout and ultrasound: the disease of kings and the queen of imaging. Gout Hyperuricaemia. 2014;1:94–100. [Google Scholar]

59. Bloch C., Hermann G., Yu T.F. A radiologic reevaluation of gout: a study of 2,000 patients. AJR Am J Roentgenol. 1980;134(4):781–787. [PubMed] [Google Scholar]

60. Malghem J, Vande Berg B, Lecouvet F. Goutte d’hier et d’aujourd’hui. Imagerie de l’appareil musculo-squlettique: Textes choisis. Montpellier (France): Sauramps Medical; 2011. p. 35–44.

61. Omoumi P., Zufferey P., Malghem J., So A. Imaging in gout and other crystal-related arthropathies. Rheum Dis Clin North Am. 2016;42(4):621–644. [PubMed] [Google Scholar]

62. Martel W. The overhanging margin of bone: a roentgenologic manifestation of gout. Radiology. 1968;91(4):755–756. [PubMed] [Google Scholar]

63. Gentili A. Advanced imaging of gout. Semin Musculoskelet Radiol. 2003;7(3):165–174. [PubMed] [Google Scholar]

64. Choi M.H., MacKenzie J.D., Dalinka M.K. Imaging features of crystal-induced arthropathy. Rheum Dis Clin North Am. 2006;32(2):427–446. viii. [PubMed] [Google Scholar]

65. Gentili A. The advanced imaging of gouty tophi. Curr Rheumatol Rep. 2006;8(3):231–235. [PubMed] [Google Scholar]

66. Durcan L., Grainger R., Keen H.I., Taylor W.J., Dalbeth N. Imaging as a potential outcome measure in gout studies: A systematic literature review. Semin Arthritis Rheum. 2016;45(5):570–579. [PubMed] [Google Scholar]

67. Dalbeth N., Clark B., McQueen F., Doyle A., Taylor W. Validation of a radiographic damage index in chronic gout. Arthritis Rheum. 2007;57(6):1067–1073. [PubMed] [Google Scholar]

68. Nestorova R., Fodor D. Crystal-induced arthritis. In: El Miedany Y., editor. Musculoskeletal ultrasonography in rheumatic diseases. Springer International Publishing; Cham: 2015. pp. 137–167. [Google Scholar]

69. Grassi W., Gutierrez M., Filippucci E. Chapter 16 - crystal-associated synovitis A2 – Wakefield, Richard J. In: D'Agostino M.A., editor. Essential applications of musculoskeletal ultrasound in rheumatology. Content Repository Only!; Philadelphia: 2010. pp. 187–197. [Google Scholar]

70. Filippucci E., Di Geso L., Grassi W. Tips and tricks to recognize microcrystalline arthritis. Rheumatol (Oxford, England) 2012;51(Suppl 7):vii18–vii21. [PubMed] [Google Scholar]

71. Gutierrez M., Smith W., Thiele R., Keen H., Kaeley G., Naredo E. Defining elementary ultrasound lesions in gout. Preliminary results of Delphi consensus and web-exercise reliability. Ann Rheum Dis. 2014;73(Suppl 2):302. [Google Scholar]

72. Wright S.A., Filippucci E., McVeigh C., Grey A., McCarron M., Grassi W. High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study. Ann Rheum Dis. 2007;66(7):859–864. [PMC free article] [PubMed] [Google Scholar]

73. Filippucci E., Riveros M.G., Georgescu D., Salaffi F., Grassi W. Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study. Osteoarthr Cartilage. 2009;17(2):178–181. [PubMed] [Google Scholar]

74. Thiele R.G., Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int. 2010;30(4):495–503. [PubMed] [Google Scholar]

75. Thiele R.G., Schlesinger N. Diagnosis of gout by ultrasound. Rheumatol (Oxford, England) 2007;46(7):1116–1121. [PubMed] [Google Scholar]

76. Naredo E., Uson J., Jimenez-Palop M., Martinez A., Vicente E., Brito E. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis. 2014;73(8):1522–1528. [PubMed] [Google Scholar]

77. Abate M., Schiavone C., Salini V., Andia I. Occurrence of tendon pathologies in metabolic disorders. Rheumatol (Oxford, England) 2013;52(4):599–608. [PubMed] [Google Scholar]

78. Dalbeth N., Clark B., Gregory K., Gamble G., Sheehan T., Doyle A. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann Rheum Dis. 2009;68(8):1290–1295. [PubMed] [Google Scholar]

79. McQueen F.M., Doyle A., Dalbeth N. Imaging in gout–what can we learn from MRI, CT, DECT and US? Arthritis Res Therapy. 2011;13(6):246. [PMC free article] [PubMed] [Google Scholar]

80. Gerster J.C., Landry M., Dufresne L., Meuwly J.Y. Imaging of tophaceous gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography. Ann Rheum Dis. 2002;61(1):52–54. [PMC free article] [PubMed] [Google Scholar]

81. Dalbeth N., Clark B., Gregory K., Gamble G.D., Doyle A., McQueen F.M. Computed tomography measurement of tophus volume: Comparison with physical measurement. Arthritis Care Res. 2007;57(3):461–465. [PubMed] [Google Scholar]

82. Perez-Ruiz F., Calabozo M., Pijoan J.I., Herrero-Beites A.M., Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Care Res. 2002;47(4):356–360. [PubMed] [Google Scholar]

83. Gerster J.C., Landry M., Duvoisin B., Rappoport G. Computed tomography of the knee joint as an indicator of intraarticular tophi in gout. Arthritis Rheum. 1996;39(8):1406–1409. [PubMed] [Google Scholar]

84. Omoumi P., Becce F., Ott J.G., Racine D., Verdun F.R. Optimization of radiation dose and image quality in musculoskeletal CT: emphasis on iterative reconstruction techniques (Part 1) Semin Musculoskelet Radiol. 2015;19(5):415–421. [PubMed] [Google Scholar]

85. Omoumi P., Verdun F.R., Becce F. Optimization of radiation dose and image quality in musculoskeletal CT: emphasis on iterative reconstruction techniques (Part 2) Semin musculoskelet Radiol. 2015;19(5):422–430. [PubMed] [Google Scholar]

86. Omoumi P., Becce F., Racine D., Ott J.G., Andreisek G., Verdun F.R. Dual-Energy CT: basic principles, technical approaches, and applications in musculoskeletal imaging (Part 1) Semin Musculoskelet Radiol. 2015;19(5):431–437. [PubMed] [Google Scholar]

87. Nicolaou S. Invited commentary. Radio Graph. 2011;31(5):1376–1377. [Google Scholar]

88. Huppertz A., Hermann K.G., Diekhoff T., Wagner M., Hamm B., Schmidt W.A. Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout. Rheumatol Int. 2014;34(6):763–771. [PubMed] [Google Scholar]

89. Bongartz T., Glazebrook K.N., Kavros S.J., Murthy N.S., Merry S.P., Franz W.B., 3rd Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis. 2015;74(6):1072–1077. [PMC free article] [PubMed] [Google Scholar]

90. Melzer R., Pauli C., Treumann T., Krauss B. Gout tophus detection-a comparison of dual-energy CT (DECT) and histology. Semin Arthritis Rheum. 2014;43(5):662–665. [PubMed] [Google Scholar]

91. McQueen F.M., Doyle A.J., Reeves Q., Gamble G.D., Dalbeth N. DECT urate deposits: now you see them, now you don't. Ann Rheum Dis. 2013;72(3):458–459. [PubMed] [Google Scholar]

92. Glazebrook K.N., Guimaraes L.S., Murthy N.S., Black D.F., Bongartz T., Manek N.J. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology. 2011;261(2):516–524. [PubMed] [Google Scholar]

93. Chowalloor P.V., Siew T.K., Keen H.I. Imaging in gout: A review of the recent developments. Therap Adv Musculoskelet Dis. 2014;6(4):131–143. [PMC free article] [PubMed] [Google Scholar]

94. Toprover M., Krasnokutsky S., Pillinger M.H. Gout in the spine: imaging, diagnosis, and outcomes. Curr Rheumatol Rep. 2015;17(12):70. [PubMed] [Google Scholar]

95. Zheng Z.F., Shi H.L., Xing Y., Li D., Jia J.Y., Lin S. Thoracic cord compression due to ligamentum flavum gouty tophus: a case report and literature review. Spinal Cord. 2015;53(12):881–886. [PMC free article] [PubMed] [Google Scholar]

96. Nunes E.A., Rosseti A.G., Jr., Ribeiro D.S., Santiago M. Gout initially mimicking rheumatoid arthritis and later cervical spine involvement. Case Rep Rheumatol. 2014;2014:357826. [PMC free article] [PubMed] [Google Scholar]

97. Ahmad I., Tejada J.G. Spinal gout: a great mimicker. A case report and literature review. Neuroradiol J. 2012;25(5):621–625. [PubMed] [Google Scholar]

98. Nygaard H.B., Shenoi S., Shukla S. Lower back pain caused by tophaceous gout of the spine. Neurology. 2009;73(5):404. [PMC free article] [PubMed] [Google Scholar]

99. Hsu C.Y., Shih T.T., Huang K.M., Chen P.Q., Sheu J.J., Li Y.W. Tophaceous gout of the spine: MR imaging features. Clin Radiol. 2002;57(10):919–925. [PubMed] [Google Scholar]

100. Gongidi P., Gough-Fibkins S. Spondyloarthritis: a gouty display. J Radiol Case Rep. 2010;4(5):13–18. [PMC free article] [PubMed] [Google Scholar]

101. Zhao Z., Wang Y., Jin J., Deng X., Huang F. An analysis of abnormal magnetic resonance imaging of sacroiliac joints in patients misdiagnosed as spondyloarthritis. Zhonghua nei ke za zhi. 2014;53(9):724–729. [PubMed] [Google Scholar]

102. Kang H.J., Jung S.H., Yoon H.K., Hahn S.B., Kim S.J. Carpal tunnel syndrome caused by space occupying lesions. Yonsei Med J. 2009;50(2):257–261. [PMC free article] [PubMed] [Google Scholar]

103. Chen C.K., Chung C.B., Yeh L., Pan H.B., Yang C.F., Lai P.H. Carpal tunnel syndrome caused by tophaceous gout: CT and MR imaging features in 20 patients. AJR Am J Roentgenol. 2000;175(3):655–659. [PubMed] [Google Scholar]

104. Godfrin-Valnet M., Godfrin G., Godard J., Prati C., Toussirot E., Michel F. Eighteen cases of crowned dens syndrome: Presentation and diagnosis. Neurochirurgie. 2013;59(3):115–120. [PubMed] [Google Scholar]

105. Udayakumar D., Kteleh T., Alfata S., Bali T., Joseph A. Spinal gout mimicking paraspinal abscess: A case report. J Radiol Case Rep. 2010;4(6):15–20. [PMC free article] [PubMed] [Google Scholar]

106. Chen C.H., Chen C.K., Yeh L.R., Pan H.B., Yang C.F. Intra-abdominal gout mimicking pelvic abscess. Skeletal Radiol. 2005;34(4):229–233. [PubMed] [Google Scholar]

107. Grainger R., Dalbeth N., Keen H., Durcan L., Lawrence Edwards N., Perez-Ruiz F. Imaging as an outcome measure in gout studies: report from the OMERACT gout working group. J Rheumatol. 2015;42(12):2460–2464. [PMC free article] [PubMed] [Google Scholar]

108. Dalbeth N., Choi H.K., Terkeltaub R. Review: gout: a roadmap to approaches for improving global outcomes. Arthritis Rheumatol. 2017;69(1):22–34. [PMC free article] [PubMed] [Google Scholar]

109. Doherty M., Jansen T.L., Nuki G., Pascual E., Perez-Ruiz F., Punzi L. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71(11):1765–1770. [PubMed] [Google Scholar]

110. Khanna D., Fitzgerald J.D., Khanna P.P., Bae S., Singh M.K., Neogi T. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64(10):1431–1446. [PMC free article] [PubMed] [Google Scholar]

111. Khanna D., Khanna P.P., Fitzgerald J.D., Singh M.K., Bae S., Neogi T. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012;64(10):1447–1461. [PMC free article] [PubMed] [Google Scholar]

112. Richette P., Doherty M., Pascual E., Barskova V., Becce F., Castaneda-Sanabria J. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42. [PubMed] [Google Scholar]

113. De Vera M.A., Marcotte G., Rai S., Galo J.S., Bhole V. Medication adherence in gout: a systematic review. Arthritis Care Res (Hoboken) 2014;66(10):1551–1559. [PubMed] [Google Scholar]

114. Terkeltaub R.A., Furst D.E., Bennett K., Kook K.A., Crockett R.S., Davis M.W. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–1068. [PubMed] [Google Scholar]

115. Terkeltaub R.A., Furst D.E., Digiacinto J.L., Kook K.A., Davis M.W. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226–2237. [PubMed] [Google Scholar]

116. Boonmuang P., Nathisuwan S., Chaiyakunapruk N., Suwankesawong W., Pokhagul P., Teerawattanapong N. Characterization of statin-associated myopathy case reports in Thailand using the health product vigilance center database. Drug Saf. 2013;36(9):779–787. [PubMed] [Google Scholar]

117. Kuncl R.W., Duncan G., Watson D., Alderson K., Rogawski M.A., Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316(25):1562–1568. [PubMed] [Google Scholar]

118. Janssens H.J., Janssen M., van de Lisdonk E.H., van Riel P.L., van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371(9627):1854–1860. [PubMed] [Google Scholar]

119. Man C.Y., Cheung I.T., Cameron P.A., Rainer T.H. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49(5):670–677. [PMC free article] [PubMed] [Google Scholar]

120. Rainer T.H., Cheng C.H., Janssens H.J., Man C.Y., Tam L.S., Choi Y.F. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med. 2016;164(7):464–471. [PubMed] [Google Scholar]

121. Richette P., Bardin T. Should prednisolone be first-line therapy for acute gout? Lancet. 2008;372(9646):1301. author reply -2. [PubMed] [Google Scholar]

122. Daoussis D., Antonopoulos I., Yiannopoulos G., Andonopoulos A.P. ACTH as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine. 2013;80(3):291–294. [PubMed] [Google Scholar]

123. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28. [PMC free article] [PubMed] [Google Scholar]

124. Ottaviani S., Molto A., Ea H.K., Neveu S., Gill G., Brunier L. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123. [PMC free article] [PubMed] [Google Scholar]

125. Schlesinger N., Alten R.E., Bardin T., Schumacher H.R., Bloch M., Gimona A. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–1848. [PubMed] [Google Scholar]

126. Qaseem A., Harris R.P., Forciea M.A. Management of acute and recurrent gout: a clinical practice guideline from the american college of physicians. Ann Intern Med. 2017;166(1):58–68. [PubMed] [Google Scholar]

127. Rees F., Jenkins W., Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72(6):826–830. [PubMed] [Google Scholar]

128. Dalbeth N., Wong S., Gamble G.D., Horne A., Mason B., Pool B. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis. 2010;69(9):1677–1682. [PubMed] [Google Scholar]

129. Zhu Y., Zhang Y., Choi H.K. The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology (Oxford) 2010;49(12):2391–2399. [PMC free article] [PubMed] [Google Scholar]

130. Beyl R.N., Jr., Hughes L., Morgan S. Update on importance of diet in gout. Am J Med. 2016;129(11):1153–1158. [PubMed] [Google Scholar]

131. Azadbakht L., Mirmiran P., Esmaillzadeh A., Azizi T., Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care. 2005;28(12):2823–2831. [PubMed] [Google Scholar]

132. Kontogianni M.D., Chrysohoou C., Panagiotakos D.B., Tsetsekou E., Zeimbekis A., Pitsavos C. Adherence to the Mediterranean diet and serum uric acid: the ATTICA study. Scand J Rheumatol. 2012;41(6):442–449. [PubMed] [Google Scholar]

133. Kiltz U., Smolen J., Bardin T., Cohen Solal A., Dalbeth N., Doherty M. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2016 [PubMed] [Google Scholar]

134. Latourte A., Bardin T., Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford) 2014;53(11):1920–1926. [PubMed] [Google Scholar]

135. Nidorf S.M., Eikelboom J.W., Budgeon C.A., Thompson P.L. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–410. [PubMed] [Google Scholar]

136. Richette P., Perez-Ruiz F., Doherty M., Jansen T.L., Nuki G., Pascual E. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10(11):654–661. [PubMed] [Google Scholar]

137. Roberts C.J., Marshall A.J., Heaton S., Barritt D.W. Comparison of natriuretic, uricosuric, and antihypertensive properties of tienilic acid, bendrofluazide, and spironolactone. BMJ. 1979;1(6158):224–226. [PMC free article] [PubMed] [Google Scholar]

138. Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011;78(5):456–459. [PubMed] [Google Scholar]

139. Greene M.L., Fujimoto W.Y., Seegmiller J.E. Urinary xanthine stones–a rare complications of allopurinol therapy. N Engl J Med. 1969;280(8):426–427. [PubMed] [Google Scholar]

140. Wright D.F., Duffull S.B., Merriman T.R., Dalbeth N., Barclay M.L., Stamp L.K. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016;81(2):277–289. [PMC free article] [PubMed] [Google Scholar]

141. Roberts R.L., Wallace M.C., Phipps-Green A.J., Topless R., Drake J.M., Tan P. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 2016 [PubMed] [Google Scholar]

142. Annemans L., Spaepen E., Gaskin M., Bonnemaire M., Malier V., Gilbert T. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67(7):960–966. [PMC free article] [PubMed] [Google Scholar]

143. Delbarre F., Amor B., Auscher C., de Gery A. Treatment of gout with allopurinol. A study of 106 cases. Ann Rheum Dis. 1966;25(6 Suppl):627–633. [PMC free article] [PubMed] [Google Scholar]

144. Becker M.A., Schumacher H.R., Jr, Wortmann R.L., MacDonald P.A., Eustace D., Palo W.A. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461. [PubMed] [Google Scholar]

145. Schumacher H.R., Jr, Becker M.A., Wortmann R.L., Macdonald P.A., Hunt B., Streit J. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540–1548. [PubMed] [Google Scholar]

146. Becker M.A., Fitz-Patrick D., Choi H.K., Dalbeth N., Storgard C., Cravets M. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015;45(2):174–183. [PubMed] [Google Scholar]

147. Reinders M.K., van Roon E.N., Jansen T.L., Delsing J., Griep E.N., Hoekstra M. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68(1):51–56. [PubMed] [Google Scholar]

148. Tam S., Carroll W. Allopurinol hepatotoxicity. Am J Med. 1989;86(3):357–358. [PubMed] [Google Scholar]

149. Greenberg M.S., Zambrano S.S. Aplastic agranulocytosis after allopurinol therapy. Arthritis Rheum. 1972;15(4):413–416. [PubMed] [Google Scholar]

150. Gelbart D.R., Weinstein A.B., Fajardo L.F. Allopurinol-induced interstitial nephritis. Ann Intern Med. 1977;86(2):196–198. [PubMed] [Google Scholar]

151. Azulay J.P., Blin O., Valentin P., Abegg P., Pellissier J.F., Serratrice G. Regression of allopurinol-induced peripheral neuropathy after drug withdrawal. Eur Neurol. 1993;33(3):193–194. [PubMed] [Google Scholar]

152. Sidoroff A., Halevy S., Bavinck J.N., Vaillant L., Roujeau J.C. Acute generalized exanthematous pustulosis (AGEP)–a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113–119. [PubMed] [Google Scholar]

153. Bastuji-Garin S., Rzany B., Stern R.S., Shear N.H., Naldi L., Roujeau J.C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–96. [PubMed] [Google Scholar]

154. Kardaun S.H., Sidoroff A., Valeyrie-Allanore L., Halevy S., Davidovici B.B., Mockenhaupt M. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609–611. [PubMed] [Google Scholar]

155. Kim S.C., Newcomb C., Margolis D., Roy J., Hennessy S. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res (Hoboken) 2013;65(4):578–584. [PMC free article] [PubMed] [Google Scholar]

156. Yang C.Y., Chen C.H., Deng S.T., Huang C.S., Lin Y.J., Chen Y.J. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan. JAMA Intern Med. 2015;175(9):1550–1557. [PubMed] [Google Scholar]

157. Hung S.I., Chung W.H., Liou L.B., Chu C.C., Lin M., Huang H.P. HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134–4139. [PMC free article] [PubMed] [Google Scholar]

158. Ng C.Y., Yeh Y.T., Wang C.W., Hung S.I., Yang C.H., Chang Y.C. Impact of the HLA-B(∗)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J Invest Dermatol. 2016;136(7):1373–1381. [PubMed] [Google Scholar]

159. Stamp L.K., Taylor W.J., Jones P.B., Dockerty J.L., Drake J., Frampton C. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529–2536. [PubMed] [Google Scholar]

160. Hande K.R., Noone R.M., Stone W.J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47–56. [PubMed] [Google Scholar]

161. Chung W.H., Chang W.C., Stocker S.L., Juo C.G., Graham G.G., Lee M.H. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157–2164. [PubMed] [Google Scholar]

162. Ko T.M., Tsai C.Y., Chen S.Y., Chen K.S., Yu K.H., Chu C.S. Use of HLA-B∗58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015;351:h4848. [PMC free article] [PubMed] [Google Scholar]

163. Dalbeth N., Kumar S., Stamp L., Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33(8):1646–1650. [PubMed] [Google Scholar]

164. Stamp L.K., O'Donnell J.L., Zhang M., James J., Frampton C., Barclay M.L. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412–421. [PubMed] [Google Scholar]

165. Juge P.A., Truchetet M.E., Pillebout E., Ottaviani S., Vigneau C., Loustau C. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2016 [PubMed] [Google Scholar]

166. Chou H.Y., Chen C.B., Cheng C.Y., Chen Y.A., Ng C.Y., Kuo K.L. Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS) J Clin Pharm Ther. 2015;40(6):689–692. [PubMed] [Google Scholar]

167. Bardin T., Chales G., Pascart T., Flipo R.M., Korng Ea H., Roujeau J.C. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine. 2016;83(3):314–317. [PubMed] [Google Scholar]

168. MacDonald T.M., Ford I., Nuki G., Mackenzie I.S., De Caterina R., Findlay E. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014;4(7):e005354. [PMC free article] [PubMed] [Google Scholar]

169. Gutman A.B., Yu T.F. Benemid (p-di-n-propylsulfamyl)-benzoic acid) as uricosuric agent in chronic gouty arthritis. Trans Assoc Am Physicians. 1951;64:279–288. [PubMed] [Google Scholar]

170. Pui K., Gow P.J., Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol. 2013;40(6):872–876. [PubMed] [Google Scholar]

171. Perez-Ruiz F., Alonso-Ruiz A., Calabozo M., Herrero-Beites A., Garcia-Erauskin G., Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57(9):545–549. [PMC free article] [PubMed] [Google Scholar]

172. Perez-Ruiz F., Calabozo M., Fernandez-Lopez M.J., Herrero-Beites A., Ruiz-Lucea E., Garcia-Erauskin G. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol. 1999;5(2):49–55. [PubMed] [Google Scholar]

173. Bardin T., Keenan R.T., Khanna P.P., Kopicko J., Fung M., Bhakta N. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study) Ann Rheum Dis. 2016 [PMC free article] [PubMed] [Google Scholar]

174. Saag K.G., Fitz-Patrick D., Kopicko J., Fung M., Bhakta N., Adler S. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study) Arthritis Rheumatol. 2017;69(1):203–212. [PubMed] [Google Scholar]

175. Takahashi S., Moriwaki Y., Yamamoto T., Tsutsumi Z., Ka T., Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003;62(6):572–575. [PMC free article] [PubMed] [Google Scholar]

176. Milionis H.J., Kakafika A.I., Tsouli S.G., Athyros V.G., Bairaktari E.T., Seferiadis K.I. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148(4):635–640. [PubMed] [Google Scholar]

177. Richette P., Briere C., Hoenen-Clavert V., Loeuille D., Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol. 2007;34(10):2093–2098. [PubMed] [Google Scholar]

178. Sundy J.S., Baraf H.S., Yood R.A., Edwards N.L., Gutierrez-Urena S.R., Treadwell E.L. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711–720. [PubMed] [Google Scholar]

179. Vallon V., Thomson S.C. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215–225. [PMC free article] [PubMed] [Google Scholar]

180. Strauss M.B. Little Brown & Co.; USA: 1968. Familiar medical quotations. [Google Scholar]